Neutrisci provides update on Tabletz and previously announced project development
VANCOUVER, BC / ACCESSWIRE / July 7, 2021 / NeutriSci International Inc. (“NeutriSci” or the “Company”)(TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), an innovative technology company developing products, licensing intellectual property and technology for B2B partnerships and the nutraceutical industry, is pleased to provide an update on previously announced projects.
Biople: Biople’s trusted reputation with consumers has made it the # 1 retailer of premium, quality CBD and CBD products in Japan. Biople, from CosmeKitchen (biople.jp) has 22 sites in Kanto, Tokai, Kinki, Chugoku / Shikoku, Kyushu-Okinawa; specializing in a range of organic cosmetics, beauty products, fashion accessories, mail order and sale of organic food.
During the brand’s short selling period on Biople shelves, sales of the Tabletz brand have been brisk, overwhelmingly positive and well received by Biople consumers. The Company looks forward to the next phase of sales and development of the Tabletz brand.
Update of the Pacwest manufacturing project: The lines for the packaging were received by NeutriSci’s manufacturing partner, Pacwest, from their customer. The information for the packaging is being finalized and will be sent to the packaging manufacturers for production. The use of the Company’s intellectual property and technology to aid in production is expected to begin in the coming weeks. Discussions around potential future projects with Pacwest involve several possible scenarios such as ingredient sales, use of technology and access to the Company’s packaging infrastructure. The financial terms of production agreements with its partners range from royalty percentages to revenues from the sale of ingredients and packaging. Each potential project will generate one or more of these sources of income. Discussions around the product mix include several different SKUs.
Glen Rehman, CEO of NeutriSci, commented: âWe continue to develop our B2B partnerships and create scenarios where our technology, intellectual property and infrastructure can be leveraged by B2B partners. The income streams for each of the opportunities we build are different depending on the project we are supporting. The Tabletz product has been very well received. We are delighted with the evolution of sales. Although still early, this leading indicator validates our expectations. We look forward to seeing the Tabletz brand become one of the top selling CBD products in Japan. “
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceuticals. Founded in 2009, NeutriSci’s builds sustainable sales models with convenience, chain, mass market and supermarket retailers for its products offering co-branding opportunities as well as private label opportunities and manufacturing services. under contract. For more information, please visit: www.neutrisci.com.
On behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Phone. : (403) 264-6320
For investor inquiries, please contact firstname.lastname@example.org
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may include forward-looking statements subject to risks and uncertainties. All statements contained, other than statements of historical fact, should be considered forward-looking. Although the Company believes that the expectations expressed in these forward-looking statements are based on reasonable assumptions, these statements are not guarantees of future performance and actual results or developments may differ materially from those of forward-looking statements. Factors that could cause actual results to differ materially from forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurance that any such statement will prove to be correct and, therefore, readers are urged to rely on their own assessment of these uncertainties. We assume no obligation to update any forward-looking statements, except as required by applicable law.
The statements contained in this press release have not been evaluated by the Food and Drug Administration. The products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
SOURCE: NeutriSci International Inc
See the source version on accesswire.com: